Breathe Well Live Well
|
Breaking: Sunovion axes sales reps for asthma meds in consolidation move
FiercePharma The company is consolidating its national respiratory sales organization, laying off a number of reps to streamline how it promotes its allergy and asthma drugs, according to an emailed statement provided to FiercePharma by the drugmaker's vice … Sunovion to lay off drug reps, reportedly by the hundreds |
View full post on asthma – Google News
|
Pfizer wins right to challenge Prempro damages award; Asthma market flat until …
FiercePharma Item > The asthma drug market will remain flat at around $14.4 billion through 2020, thanks in part to generic rivals for Merck's ($MRK)Singulair, Decision Resources concludes. Release > Teva Pharmaceutical Industries ($TEVA) won an appeals court's … |
View full post on asthma – Google News
|
Sanofi licenses hard-to-make asthma drug to Acton
FiercePharma Manufacturing Acton used the same approach in 2009–one year after it was formed–with Forest Labs ($FRX) to win a licensing deal for asthma treatment Aerospan. The NDA for this HFA-propelled aerosol inhaled corticosteroid was approved by the FDA in 2006. … Acton Pharmaceuticals, Inc. Announces License Agreement With |
View full post on asthma – Google News
|
Sweden approves copy of GSK asthma blockbuster
FiercePharma Swedish regulators have approved a knock-off version of the asthma drug, which brought in more than $8 billion in 2010 sales for GSK, paving the way for it to be sold in Germany, Italy, Portugal, Hungary and the Czech and Slovak Republics, … Glaxo's Advair Faces Sales Decline on Swedish Generic Approval Glaxo's Advair Faces Sales Decline on Swedish Generic Approval |
View full post on asthma – Google News
|
Valeant taps CEO Pearson as chairman; Asthma drug helps kids with milk allergies;
FiercePharma Report > Novartis and Roche's Xolair, a medication used to treat asthma attacks caused by allergens such as pollen and dust mites, helped children overcome milk allergies, a small study showed. News > Pozen filed a motion to prevent generic drugmaker … |
View full post on asthma – Google News
|
NICE nixes Novartis asthma med for young kids; Stada sales suffer on European …
FiercePharma NICE has refused to back the use of Novartis' Xolair for young children, saying the asthma drug's cost brings little extra benefits over existing treatments … |
View full post on asthma – Google News